Revesz Syndrome: Comprehensive Disease-Characteristics Report

Target entity: Revesz syndrome (RS), a severe, early-onset telomere biology disorder (TBD), usually caused by heterozygous pathogenic TINF2 variants and characterized by early bone-marrow failure, bilateral exudative retinopathy, and intracranial abnormalities.

Evidence boundary. RS is exceptionally rare. The strongest RS-specific quantitative source remains the systematic review of 18 children published by Karremann et al. on 7 October 2020 (DOI: 10.1186/s13023-020-01553-y). No 2023–2024 RS-specific cohort superseding it was identified. Consequently, this report labels recommendations derived from the broader DC/TBD literature as TBD extrapolation, rather than presenting them as demonstrated RS evidence. The underlying data are aggregated disease-level literature and case reports, not individual-level EHR data. (karremann2020reveszsyndromerevisited pages 8-9, karremann2020reveszsyndromerevisited pages 1-2, rolles2024inheritedtelomerebiology pages 8-9)

The following table provides a knowledge-base-oriented synopsis.

Table: This table condenses the strongest retrieved evidence for Revesz syndrome across identifiers, genetics, phenotype, mechanism, diagnosis, prognosis, treatment, trials, and evidence gaps. It distinguishes Revesz-specific findings from broader telomere biology disorder extrapolations for knowledge-base use.

1. Disease information

Definition

RS is an ultra-rare, severe pediatric variant within the dyskeratosis congenita/telomere biology disorder spectrum. Its defining clinical combination is bilateral exudative retinopathy, early progressive marrow failure, and CNS abnormalities—particularly intracranial calcification and cerebellar hypoplasia. Unlike classic dyskeratosis congenita, the complete mucocutaneous triad of nail dystrophy, reticular pigmentation, and oral leukoplakia is uncommon at presentation, probably because RS begins and progresses before all age-dependent features can develop. (karremann2020reveszsyndromerevisited pages 8-9, karremann2020reveszsyndromerevisited pages 7-8, karremann2020reveszsyndromerevisited pages 1-2)

A concise direct quotation from the 2020 abstract is: “RS is a severe variant of DKC with early bone marrow failure and retinopathy in all patients.” (karremann2020reveszsyndromerevisited pages 1-2)

Identifiers and synonyms

• MONDO: MONDO:0009990.
• OMIM: #268130.
• MeSH: no uniquely retrieved RS descriptor; use the broader Dyskeratosis Congenita, D019871, with an RS subtype annotation.
• ClinicalTrials.gov/MeSH supplementary concept: “Revesz Debuse syndrome,” concept C538371.
• ICD-10/ICD-11: no specific RS code was identified. Coding generally falls under congenital marrow-failure, dyskeratosis congenita, retinal, and neurologic manifestations, depending on jurisdiction.
• Synonyms: Revesz syndrome; Revesz–Debuse syndrome; Revesz type dyskeratosis congenita; TINF2-associated Revesz syndrome; TINF2-associated dyskeratosis congenita with bilateral exudative retinopathy and intracranial calcification. (OpenTargets Search: Revesz syndrome-TINF2, karremann2020reveszsyndromerevisited pages 1-2, NCT06817590 chunk 2)

Open Targets links MONDO:0009990 specifically to TINF2/ENSG00000092330, supported by five association evidence records and literature including PMID 18252230 and 21477109. (OpenTargets Search: Revesz syndrome-TINF2)

2. Etiology

Causal factor

RS is primarily a germline Mendelian disorder caused by heterozygous pathogenic variants in TINF2, encoding TIN2, a central shelterin-complex protein. The causal lesion is constitutional rather than infectious, toxic, or acquired. Most genetically characterized RS cases have apparently de novo variants, although TINF2-related TBDs can be transmitted as autosomal-dominant disorders. (karremann2020reveszsyndromerevisited pages 7-8, sasa2012threenoveltruncating pages 1-3, savage2022dyskeratosiscongenitaand pages 8-10)

Genetic risk factors

The dominant risk factor is a pathogenic TINF2 variant, especially within the narrow exon-6 dyskeratosis-congenita hotspot. Variants reported in RS or overlapping RS/Hoyeraal–Hreidarsson phenotypes include:

• NM_001099274.1:c.845G>A, p.Arg282His, the recurrent hotspot;
• c.838A>T, p.Lys280Ter;
• c.839delA, p.Lys280ArgfsTer36, a truncating RS-associated allele;
• c.865C>T, p.Pro289Ser, reported in mosaic form in one RS case.

The historical variant series showed p.Arg282His in 12 DC probands, two DC/RS probands, one DC/HH/RS proband, and two HH probands, illustrating that a TINF2 genotype does not map uniquely to one syndromic label. (tomcikova2018whyisit pages 1-2, sasa2012threenoveltruncating pages 1-3, sasa2012threenoveltruncating pages 3-4)

Environmental, protective, and gene–environment factors

No environmental exposure is known to cause RS, and no validated genetic or environmental protective factor, modifier allele, founder effect, diet, or lifestyle intervention has been demonstrated specifically in RS. Broader TBD literature suggests that smoking, alcohol, viral infection, ionizing radiation, and pulmonary-toxic or DNA-damaging drugs may aggravate organ injury or treatment toxicity, but this is not RS-specific evidence. (rolles2024inheritedtelomerebiology pages 12-14, carvalho2022recentadvancesin pages 7-9)

3. Phenotypes

The frequencies below derive principally from 18 published children and are vulnerable to case-report ascertainment and incomplete reporting.

• Bone-marrow failure/pancytopenia: severe, progressive laboratory and clinical phenotype; effectively universal in the reviewed RS series. It occurred from 6 months to 6 years, with median onset 1.5 years; all affected children had developed it by age six. Consequences include infection, bleeding, anemia, transfusion dependence, and transplant need. Suggested HPO: HP:0001876 Pancytopenia, HP:0005528 Bone marrow hypocellularity, HP:0001903 Anemia, HP:0001873 Thrombocytopenia, HP:0001875 Neutropenia. (karremann2020reveszsyndromerevisited pages 7-8, karremann2020reveszsyndromerevisited pages 1-2)
• Bilateral exudative retinopathy: defining, severe, and progressive; present in all 15 children for whom retinal data were available. Median onset was 1.1 years (95% CI 0.7–1.5), usually at 6–18 months. It can progress to proliferative vitreoretinopathy, retinal detachment, neovascular glaucoma, blindness, and enucleation. Suggested HPO: HP:0000555 Exudative retinopathy, HP:0011003 Retinal detachment, HP:0000501 Glaucoma, HP:0000510 Blindness. (karremann2020reveszsyndromerevisited pages 8-9, karremann2020reveszsyndromerevisited pages 7-8, tomcikova2018whyisit pages 1-2)
• Intracranial calcification: imaging sign reported in approximately 85%. Suggested HPO: HP:0002514/HP:0002521 intracranial/cerebral calcification; terminology should be verified against the current HPO release. (karremann2020reveszsyndromerevisited pages 7-8)
• Cerebellar hypoplasia and ataxia: cerebellar hypoplasia in approximately 76%; generally congenital/developmental and non-reversible. Suggested HPO: HP:0001321 Cerebellar hypoplasia, HP:0001251 Ataxia. (karremann2020reveszsyndromerevisited pages 7-8, rolles2024inheritedtelomerebiology pages 8-9)
• Developmental delay/intellectual impairment: approximately 71%, usually recognized in infancy or early childhood, with variable severity. Suggested HPO: HP:0001263 Global developmental delay, HP:0001249 Intellectual disability. (karremann2020reveszsyndromerevisited pages 7-8)
• Seizures: estimated cumulative frequency approximately 20%, exclusively beginning in early childhood in the reviewed cases. Suggested HPO: HP:0001250 Seizure. (karremann2020reveszsyndromerevisited pages 1-2)
• Intracranial hemorrhage: three reviewed patients; potentially catastrophic. Suggested HPO: HP:0002170 Intracranial hemorrhage. (karremann2020reveszsyndromerevisited pages 9-11, karremann2020reveszsyndromerevisited pages 7-8)
• Growth restriction: intrauterine or postnatal, qualitatively common. Suggested HPO: HP:0001511 Intrauterine growth retardation, HP:0001510 Growth delay, HP:0004322 Short stature. (sasa2012threenoveltruncating pages 1-3, rolles2024inheritedtelomerebiology pages 8-9)
• Mucocutaneous findings: nail dystrophy was the most frequent element, with variable reticular pigmentation, oral leukoplakia, and fine/sparse hair. Only two children had the full classic DC triad. Suggested HPO: HP:0001597 Abnormality of the nail, HP:0009713 Nail dystrophy, HP:0001000 Abnormality of skin pigmentation, HP:0002745 Oral leukoplakia, HP:0002219 Sparse hair. (karremann2020reveszsyndromerevisited pages 8-9, rolles2024inheritedtelomerebiology pages 8-9)

No RS-specific EQ-5D, SF-36, PROMIS, or other standardized quality-of-life measurements were identified. Nevertheless, blindness, developmental disability, transfusion dependence, infection risk, and repeated hospitalization imply profound effects on mobility, education, communication, independence, and family burden. A completed NIH needs-assessment study enrolled 53 DC/TBD patients and caregivers, but it was not RS-specific. (NCT04959188 chunk 1)

4. Genetic and molecular information

Gene and protein

• Gene: TINF2, TERF1 interacting nuclear factor 2.
• Ensembl: ENSG00000092330.
• Protein: TIN2, a shelterin component linking TRF1/TRF2 to TPP1/POT1.
• Inheritance: autosomal dominant, usually de novo in severe pediatric TINF2 disease.
• Origin: constitutional/germline; mosaicism has occasionally been reported. These are not characteristically somatic cancer-driver lesions. (OpenTargets Search: Revesz syndrome-TINF2, nelson2018thecterminalextension pages 1-3, savage2022dyskeratosiscongenitaand pages 8-10)

Variant classes and consequences

Both missense and truncating alleles occur. Stable truncated TIN2 protein was demonstrated in patient-derived lymphoblastoid cells, arguing against a simple null/haploinsufficiency model for all alleles. A truncation markedly impaired TIN2–TRF1 interaction, whereas common p.Arg282His had a smaller effect on that particular interaction. TINF2 pathogenesis is therefore best annotated as multifactorial altered-function/dominant dysfunction, with variant-dependent effects on shelterin organization, telomerase regulation, telomere cohesion, and end protection; a universal dominant-negative mechanism has not been proven. (sasa2012threenoveltruncating pages 1-3, nelson2018thecterminalextension pages 1-3, savage2022dyskeratosiscongenitaand pages 8-10)

The biochemical abstract states: “TIN2 is central to the shelterin complex, linking the telomeric proteins TRF1 and TRF2 with TPP1/POT1.” It further concludes that TIN2 isoforms are functionally distinguishable and that shelterin composition may be altered in patients with TINF2 mutations. (nelson2018thecterminalextension pages 1-3)

Population allele frequencies were not available in the retrieved evidence. Given severe early-onset disease and frequent de novo occurrence, established pathogenic RS alleles are expected to be absent or extremely rare in population databases, but each HGVS allele must be checked directly in current gnomAD and ClinVar before database ingestion. No recurrent RS-associated chromosomal rearrangement, aneuploidy, or large structural variant was identified.

Modifiers and epigenetics

No validated RS modifier gene or disease-specific epigenetic signature is known. Somatic reversion has been reported in TINF2-related TBD more broadly and may obscure blood-based variant detection, occasionally making fibroblast DNA testing necessary. This has not been established as a protective mechanism in RS. (savage2022dyskeratosiscongenitaand pages 8-10)

5. Environmental information

RS is not infectious and has no zoonotic or contagious component. No toxin, pollutant, occupational exposure, smoking pattern, diet, exercise level, or alcohol exposure is established as etiologic. Because telomere-deficient tissues have limited regenerative reserve, avoidance of tobacco, excessive alcohol, unnecessary radiation, and organ-toxic medications is biologically and clinically prudent under general TBD management, but evidence is indirect for RS. (rolles2024inheritedtelomerebiology pages 12-14, carvalho2022recentadvancesin pages 7-9)

6. Mechanism and pathophysiology

Ordered causal chain

1. A heterozygous germline TINF2 hotspot or truncating variant leads to altered TIN2 structure or protein interactions.
2. Altered TIN2 leads to defective integration/regulation of the TRF1–TIN2–TRF2–TPP1/POT1 shelterin network and telomerase recruitment; the exact defect is variant-dependent.
3. Shelterin/telomerase dysregulation leads to exceptionally rapid telomere attrition and/or defective telomere capping; telomerase-independent shortening has been demonstrated in a Tinf2-mutant mouse model.
4. Critically short or uncapped telomeres lead to DNA-damage signaling, chromosome instability, senescence, apoptosis, and loss of self-renewal.
5. Stem/progenitor-cell exhaustion leads directly to failure of high-turnover tissues—most demonstrably hematopoietic stem/progenitor cells—resulting in hypocellular marrow and pancytopenia.
6. Retinal branch: telomere-associated vascular/endothelial or supporting-cell dysfunction is inferred to lead to peripheral capillary nonperfusion, leakage, neovascularization, exudation, retinal detachment, glaucoma, and blindness; this cell-level sequence remains incompletely demonstrated in RS.
7. Neurodevelopmental branch: developmental telomere dysfunction is inferred to disrupt cerebellar and cerebral growth and microvascular integrity, resulting in cerebellar hypoplasia, calcification, white-matter abnormalities, developmental delay, seizures, and occasional hemorrhage.
8. Systemic branch: limited tissue regenerative capacity leads to mucocutaneous degeneration, growth restriction, infection susceptibility, and later pulmonary/hepatic complications, compounded in some patients by treatment toxicity. (karremann2020reveszsyndromerevisited pages 9-11, sasa2012threenoveltruncating pages 1-3, nelson2018thecterminalextension pages 1-3, nelson2018thecterminalextension pages 30-33, rolles2024inheritedtelomerebiology pages 2-4, rolles2024inheritedtelomerebiology pages 10-12)

Processes and ontology suggestions

Relevant GO concepts include telomere maintenance (GO:0000723), telomere organization (GO:0032200), protein localization to chromosome, telomeric region, DNA-damage response, cellular senescence (GO:0090398), stem-cell population maintenance (GO:0019827), and apoptotic process (GO:0006915). Relevant cellular components include nuclear chromosome telomeric region (GO:0000784) and shelterin complex. Candidate CL annotations include hematopoietic stem cell, hematopoietic progenitor cell, retinal endothelial cell, retinal pigment epithelial cell, photoreceptor cell, neuron, cerebellar granule cell, and glial cell; only hematopoietic stem-cell involvement is strongly demonstrated, while the exact retinal/CNS target populations remain uncertain.

No RS-specific transcriptomic, proteomic, metabolomic, lipidomic, single-cell, spatial-transcriptomic, or integrated multi-omics dataset was identified. DC iPSCs recapitulate telomere-maintenance defects and eventual loss of self-renewal, but the retrieved iPSC study did not specifically model RS/TINF2. (batista2011telomereshorteningand pages 1-3)

7. Anatomical structures affected

Primary sites are:

• Bone marrow/hematopoietic system—hematopoietic stem and progenitor compartments; UBERON: bone marrow.
• Both retinas and retinal vasculature—bilateral by definition; UBERON: retina, retinal blood vessel, vitreous body.
• Brain, especially cerebellum and periventricular white matter; UBERON: brain, cerebellum, cerebral white matter, ventricular system.
• Skin, nails, oral mucosa, and hair follicles.
• Secondary or later TBD-associated involvement may include lung, liver, gastrointestinal tract, kidney, and immune system.

A TINF2-DC autopsy—not a classic RS case—showed donor-derived hematopoietic tissue with age-appropriate telomeres but severe shortening in native tissues, especially lung, liver, and kidney, supporting tissue-specific vulnerability beyond marrow. (karremann2020reveszsyndromerevisited pages 7-8, karremann2020reveszsyndromerevisited pages 4-7, rolles2024inheritedtelomerebiology pages 8-9, roake2021tissuespecifictelomereshortening pages 1-2)

At the subcellular level, the principal compartment is the nucleus, particularly telomeric chromatin and shelterin at chromosome ends.

8. Temporal development

RS is congenital in genetic origin and usually manifests during infancy. Retinopathy generally appears at 6–18 months, often before or alongside hematologic disease. Marrow failure usually becomes apparent in the second year and was present by age six in all reviewed patients. Neurodevelopmental abnormalities may be evident prenatally or in early infancy; seizures, when present, begin in early childhood. The course is chronic, progressive, and lifelong, without documented spontaneous remission. (karremann2020reveszsyndromerevisited pages 7-8, karremann2020reveszsyndromerevisited pages 1-2)

There is no validated stage system. A practical clinical sequence is: congenital growth/CNS abnormality → infantile retinopathy → early cytopenias/marrow failure → progressive visual and neurologic disability → severe infections, bleeding, pulmonary complications, or transplant-related morbidity. The first 1–2 years constitute a critical window for retinal surveillance and hematologic diagnosis.

9. Inheritance and population

RS is autosomal dominant at the molecular level but is most often caused by a de novo heterozygous TINF2 variant. Recurrence risk is low but not zero when parents test negative because parental germline mosaicism cannot be excluded. An affected individual would theoretically have a 50% transmission risk, although severe childhood mortality limits observed vertical transmission. Familial TINF2 TBD shows variable expressivity; the penetrance of specific RS alleles has not been quantified. (karremann2020reveszsyndromerevisited pages 7-8, savage2022dyskeratosiscongenitaand pages 5-6, savage2022dyskeratosiscongenitaand pages 8-10)

Telomere-mediated genetic anticipation is recognized across TBDs, but direct multigenerational anticipation data for RS are lacking. No founder allele, population enrichment, consanguinity effect, or carrier frequency has been demonstrated. In the 18-child review there were 11 boys and seven girls; this small difference did not establish a biologically meaningful sex bias. No prevalence or incidence per 100,000 can be calculated reliably. (karremann2020reveszsyndromerevisited pages 7-8, rolles2024inheritedtelomerebiology pages 10-12)

10. Diagnostics

Recommended workflow

1. Recognize the combination of infantile bilateral exudative retinopathy, unexplained cytopenia/hypocellular marrow, intracranial calcification/cerebellar hypoplasia, growth restriction, or DC stigmata.
2. Obtain CBC with differential, reticulocyte count, marrow aspirate/biopsy with morphology and cytogenetics, and infection/immunologic evaluation.
3. Perform complete dilated retinal examination, wide-field imaging and fluorescein angiography where feasible; assess retinal nonperfusion, leakage, exudation, neovascularization, detachment, and glaucoma.
4. Obtain noncontrast head CT for calcification and MRI for cerebellar, callosal, white-matter, hemorrhagic, and cystic abnormalities.
5. Measure leukocyte telomere length by flow-FISH, preferably lymphocyte and granulocyte subsets. Lymphocyte length below the age-adjusted first percentile is the standard “very short” threshold; seven measured RS patients were below this threshold. (karremann2020reveszsyndromerevisited pages 7-8, rolles2024inheritedtelomerebiology pages 8-9)
6. Sequence TINF2, including exon 6, using a comprehensive TBD/inherited-marrow-failure panel. If unrevealing, use WES or WGS with copy-number analysis and consider non-blood DNA if somatic reversion/mosaicism is suspected. (rolles2024inheritedtelomerebiology pages 10-12, savage2022dyskeratosiscongenitaand pages 5-6, savage2022dyskeratosiscongenitaand pages 8-10)
7. Perform mitomycin-C or diepoxybutane chromosome-breakage testing when Fanconi anemia remains possible. CMA, karyotyping, FISH, mitochondrial testing, and repeat-expansion testing are not first-line RS tests unless another diagnosis is suspected. (rolles2024inheritedtelomerebiology pages 12-14, NCT01659606 chunk 1)

A reported RS child had telomere lengths of 2.47–2.48 kb, below the first percentile, and TINF2 c.845G>A/p.Arg282His. (karremann2020reveszsyndromerevisited pages 4-7)

Differential diagnosis

• Coats plus/CRMCC, usually CTC1, STN1 or POT1 related: retinal telangiectasia, calcifications, white-matter disease, cysts, GI bleeding, and bone disease; telomeres may be normal.
• Hoyeraal–Hreidarsson syndrome: cerebellar hypoplasia, growth restriction, immunodeficiency, microcephaly and severe marrow failure, often DKC1 or biallelic RTEL1 related; exudative retinopathy is less defining.
• Classic DC/other TBDs: mucocutaneous triad and marrow failure without the characteristic RS retinal/CNS combination.
• Fanconi anemia: congenital anomalies and marrow failure with positive chromosome-breakage testing.
• Isolated Coats disease/familial exudative vitreoretinopathy: retinal disease without very short telomeres or systemic marrow failure.
• Congenital infection and metabolic causes of intracranial calcification should be excluded based on context. (rolles2024inheritedtelomerebiology pages 8-9, NCT01659606 chunk 1)

No universally accepted RS-only diagnostic criteria exist; diagnosis is syndromic plus molecular/functional confirmation.

11. Outcome and prognosis

In the 18-child review, Kaplan–Meier median survival was 6.5 years (95% CI 3.6–9.4), and no reported patient survived beyond 12 years. These historical estimates are based on very small, heterogeneous case reports and may not reflect contemporary transplant and ophthalmic care. (karremann2020reveszsyndromerevisited pages 7-8, karremann2020reveszsyndromerevisited pages 1-2)

Major morbidity includes blindness, developmental disability, ataxia, seizures, recurrent infection, bleeding, transfusion dependence, transplant toxicity, and pulmonary failure. Three patients had intracranial hemorrhage. In a 2023 childhood DC natural-history cohort, the RS patient developed cerebral calcifications and retinopathy progressing to blindness and later died from septic shock after dental/gum infection, illustrating combined visual and immune/hematologic morbidity. (karremann2020reveszsyndromerevisited pages 9-11, karremann2020reveszsyndromerevisited pages 7-8)

Poor prognostic markers plausibly include very early marrow failure, severe retinal disease, profound telomere shortening, pre-existing pulmonary/hepatic injury, infection, hemorrhage, and inability to undergo successful transplantation. No validated RS prognostic score or biomarker beyond phenotype, organ status, blood counts, and telomere length exists.

12. Treatment

Hematologic treatment

Allogeneic hematopoietic-cell transplantation (HCT) is the only established potentially curative treatment for marrow failure, but it does not correct retinal, neurologic, pulmonary, hepatic, or other native-tissue telomere pathology. Eight of 18 reviewed RS children underwent transplantation; four were alive at last follow-up after a median of 22 months. Two reported late deaths were from pulmonary failure at two and 4.5 years after HCT. (karremann2020reveszsyndromerevisited pages 8-9, karremann2020reveszsyndromerevisited pages 9-11, karremann2020reveszsyndromerevisited pages 1-2)

Reduced-intensity, radiation-avoiding conditioning is preferred because TBD tissues are unusually sensitive to DNA-damaging chemotherapy and radiation. Four RS cases receiving fludarabine/cyclophosphamide/antithymocyte-globulin conditioning had limited acute toxicity, but long-term evidence remains weak. In broader TBD cohorts, 10-year post-HCT survival was about 23%, with progressive pulmonary fibrosis an important late complication. (karremann2020reveszsyndromerevisited pages 9-11, rolles2024inheritedtelomerebiology pages 14-15)

The active-not-recruiting phase-2 NCT01659606 explicitly includes RS and evaluates an alkylator- and radiation-free regimen of alemtuzumab plus fludarabine, followed by cyclosporine or tacrolimus and mycophenolate prophylaxis; target enrollment is 40. ClinicalTrials.gov: https://clinicaltrials.gov/study/NCT01659606. (NCT01659606 chunk 1, NCT01659606 chunk 2)

Suggested NCIT concepts: Hematopoietic Stem Cell Transplantation, Allogeneic Bone Marrow Transplantation, Reduced-Intensity Conditioning, Fludarabine, Alemtuzumab, Cyclophosphamide, and Antithymocyte Globulin.

Ophthalmic treatment

Urgent retinal treatment is warranted before irreversible detachment or glaucoma. Reported approaches include laser photocoagulation of avascular retina, cryotherapy, intravitreal bevacizumab, vitrectomy, and—when a painful blind eye develops—enucleation. Evidence consists of case reports, not comparative trials. (karremann2020reveszsyndromerevisited pages 9-11, karremann2020reveszsyndromerevisited pages 4-7, tomcikova2018whyisit pages 1-2)

One child with mosaic TINF2 p.Pro289Ser had the left eye enucleated for neovascular glaucoma, while photocoagulation of the right ischemic retina preserved reported visual acuity of 0.9 at age seven. This supports early retinal examination in every young child with unexplained aplastic anemia. (tomcikova2018whyisit pages 1-2)

Suggested NCIT concepts: Laser Photocoagulation, Cryotherapy, Bevacizumab, Intravitreal Injection, Vitrectomy, and Enucleation.

Pharmacotherapy and supportive care

Transfusions, infection prophylaxis/treatment, dental care, nutritional support, developmental therapies, low-vision services, seizure treatment, and physical/occupational/speech therapy should be individualized. Standard immunosuppressive therapy for acquired aplastic anemia generally has little benefit in constitutional TBD marrow failure. (rolles2024inheritedtelomerebiology pages 10-12, carvalho2022recentadvancesin pages 7-9)

Oral androgens such as danazol or oxymetholone can improve counts in some TBD patients, but there are no RS-specific response data. A 2024 review reported short-term hematologic responses in approximately 50–100% of heterogeneous TBD patients receiving danazol; in one underlying study, 11/12 gained telomere length (mean +386 bp) and 83% had a hematologic response at 24 months. Hepatotoxicity, virilization, lipid changes, and clonal evolution require monitoring. These figures must not be interpreted as RS response rates. (rolles2024inheritedtelomerebiology pages 12-14, rolles2024inheritedtelomerebiology pages 14-15)

Emerging therapy

NCT06817590, a phase-1 Boston Children’s Hospital study first posted 10 February 2025, explicitly includes RS. It evaluates oral deoxycytidine plus deoxythymidine three times daily for 24 weeks in 36 estimated participants aged 1–70, based on 2023 evidence that thymidine-nucleotide metabolism controls human telomere length (PMID 36959362). Outcomes include safety, blood counts, telomere length, marrow cellularity, clonal hematopoiesis, and pulmonary function. ClinicalTrials.gov: https://clinicaltrials.gov/study/NCT06817590. This is experimental and has no efficacy result yet. (NCT06817590 chunk 1, NCT06817590 chunk 2)

PAPD5 inhibition, engineered telomerase RNA, gene editing, and telomerase gene therapy remain preclinical or early translational TBD approaches. No approved RS gene, RNA, or cell therapy exists. (rolles2024inheritedtelomerebiology pages 14-15)

13. Prevention

Primary prevention by lifestyle change is impossible because RS is genetic. Reproductive options after identification of a familial pathogenic variant include genetic counseling, prenatal diagnosis, and preimplantation genetic testing. Parental testing should include discussion of possible germline mosaicism.

Secondary prevention centers on early detection: cascade testing, CBC surveillance, telomere testing where indicated, immediate retinal examination in infants with cytopenia or suspected TBD, and neuroimaging when CNS features are present. Population newborn screening is not available.

Tertiary prevention includes early laser treatment of avascular retina, prompt infection management, meticulous dental care, matched-donor screening, avoidance of affected related donors, reduced-toxicity HCT conditioning, sun protection, smoking avoidance, minimized diagnostic/therapeutic radiation, and surveillance for pulmonary, hepatic, marrow-clonal, mucosal, and malignant complications. General vaccines should follow expert guidance tailored to immune status and transplant timing; there is no RS-specific vaccine. (NCT01659606 chunk 1, savage2022dyskeratosiscongenitaand pages 5-6, carvalho2022recentadvancesin pages 7-9)

14. Other species and natural disease

No naturally occurring veterinary syndrome equivalent to human RS was identified in companion animals, livestock, or wildlife. RS has no zoonotic potential and cannot be transmitted between species. TINF2 orthologues are evolutionarily conserved in vertebrates, preserving the central shelterin role, but orthologue identifiers should be retrieved directly from current NCBI Gene/Alliance records before database deposition.

15. Model organisms and experimental systems

• Mouse: a knock-in model carrying a DC-associated Tinf2 mutation demonstrated telomerase-independent telomere shortening, supporting a direct TIN2 role beyond simply reducing telomerase activity. It models the molecular lesion but has not been shown here to reproduce the complete human RS combination of retinopathy, intracranial calcification, and infantile marrow failure. (nelson2018thecterminalextension pages 30-33)
• Human patient-derived cells: lymphoblastoid lines expressing truncating TIN2 demonstrated stable mutant protein and impaired TRF1 interaction. These are useful for shelterin biochemistry but do not reproduce tissue-level RS. (sasa2012threenoveltruncating pages 1-3)
• Engineered cell systems: overexpression and CRISPR studies distinguish TIN2S and TIN2L interactions with TRF1/TRF2 and their permissiveness for telomere elongation. (nelson2018thecterminalextension pages 1-3, nelson2018thecterminalextension pages 8-10)
• DC iPSCs: patient-derived iPSCs reproduce biochemical telomere defects and loss of self-renewal, making them a platform for therapeutic screening; however, the retrieved study modeled TERT, DKC1, and TCAB1 disease rather than RS-specific TINF2 alleles. (batista2011telomereshorteningand pages 1-3)

No validated RS retinal organoid, cerebral organoid, zebrafish, Drosophila, rat, or naturally occurring animal model was identified.

Recent developments and expert assessment

The major 2023–2024 advance is not a new RS natural-history cohort but refinement of the broader TBD framework. The July 2024 review by Rolles et al. reaffirmed RS as an early severe pediatric TBD with telomeres “considerably below the 1% percentile,” endorsed lymphocyte flow-FISH followed by germline sequencing, and emphasized reduced-intensity/radiation-avoiding HCT. DOI: 10.1159/000540109. (rolles2024inheritedtelomerebiology pages 8-9, rolles2024inheritedtelomerebiology pages 14-15)

The 2023 thymidine-metabolism study (PMID 36959362; DOI: 10.1038/s41588-023-01339-5) supplied the mechanistic basis for the subsequent RS-inclusive dC/dT phase-1 trial. This represents a transition from supportive/transplant care toward attempts to manipulate telomere substrate metabolism, although clinical benefit remains unproven. (NCT06817590 chunk 1, NCT06817590 chunk 2)

The principal expert conclusion is that RS should be managed as a multisystem developmental and degenerative disorder, not merely aplastic anemia. HCT can replace hematopoiesis but cannot repair the retina, brain, lung, or liver; successful care therefore requires coordinated hematology/transplantation, ophthalmology, neurology, genetics, pulmonology, hepatology, dentistry, rehabilitation, and psychosocial support. (karremann2020reveszsyndromerevisited pages 9-11, rolles2024inheritedtelomerebiology pages 14-15, NCT04959188 chunk 1)

Priority knowledge gaps

Reliable prevalence, incidence, penetrance, allele-specific natural history, population frequencies, germline-mosaic recurrence risk, modifier genes, protective factors, quantitative quality of life, retinal cellular mechanism, RS-specific omics, and controlled treatment outcomes are unavailable. Published percentages arise from fewer than 20 historical patients and should be stored with small-sample and ascertainment-bias qualifiers. No 2023–2024 RS-specific cohort, randomized trial, approved targeted therapy, or validated prognostic model was identified. (karremann2020reveszsyndromerevisited pages 7-8, karremann2020reveszsyndromerevisited pages 1-2, rolles2024inheritedtelomerebiology pages 8-9)

References

1. (karremann2020reveszsyndromerevisited pages 8-9): Michael Karremann, Eva Neumaier-Probst, Frank Schlichtenbrede, Fabian Beier, Tim H. Brümmendorf, Friedrich W. Cremer, Peter Bader, and Matthias Dürken. Revesz syndrome revisited. Orphanet Journal of Rare Diseases, Oct 2020. URL: https://doi.org/10.1186/s13023-020-01553-y, doi:10.1186/s13023-020-01553-y. This article has 39 citations and is from a peer-reviewed journal.

2. (karremann2020reveszsyndromerevisited pages 1-2): Michael Karremann, Eva Neumaier-Probst, Frank Schlichtenbrede, Fabian Beier, Tim H. Brümmendorf, Friedrich W. Cremer, Peter Bader, and Matthias Dürken. Revesz syndrome revisited. Orphanet Journal of Rare Diseases, Oct 2020. URL: https://doi.org/10.1186/s13023-020-01553-y, doi:10.1186/s13023-020-01553-y. This article has 39 citations and is from a peer-reviewed journal.

3. (rolles2024inheritedtelomerebiology pages 8-9): Benjamin Rolles, Mareike Tometten, Robert Meyer, Martin Kirschner, Fabian Beier, and Tim H. Brümmendorf. Inherited telomere biology disorders: pathophysiology, clinical presentation, diagnostics, and treatment. Transfusion Medicine and Hemotherapy, 51:292-309, Jul 2024. URL: https://doi.org/10.1159/000540109, doi:10.1159/000540109. This article has 23 citations and is from a peer-reviewed journal.

4. (karremann2020reveszsyndromerevisited pages 7-8): Michael Karremann, Eva Neumaier-Probst, Frank Schlichtenbrede, Fabian Beier, Tim H. Brümmendorf, Friedrich W. Cremer, Peter Bader, and Matthias Dürken. Revesz syndrome revisited. Orphanet Journal of Rare Diseases, Oct 2020. URL: https://doi.org/10.1186/s13023-020-01553-y, doi:10.1186/s13023-020-01553-y. This article has 39 citations and is from a peer-reviewed journal.

5. (OpenTargets Search: Revesz syndrome-TINF2): Open Targets Query (Revesz syndrome-TINF2, 1 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.

6. (savage2022dyskeratosiscongenitaand pages 8-10): Sharon A. Savage. Dyskeratosis congenita and telomere biology disorders. Hematology. American Society of Hematology. Education Program, 2022 1:637-648, Dec 2022. URL: https://doi.org/10.1182/hematology.2022000394, doi:10.1182/hematology.2022000394. This article has 119 citations.

7. (rolles2024inheritedtelomerebiology pages 2-4): Benjamin Rolles, Mareike Tometten, Robert Meyer, Martin Kirschner, Fabian Beier, and Tim H. Brümmendorf. Inherited telomere biology disorders: pathophysiology, clinical presentation, diagnostics, and treatment. Transfusion Medicine and Hemotherapy, 51:292-309, Jul 2024. URL: https://doi.org/10.1159/000540109, doi:10.1159/000540109. This article has 23 citations and is from a peer-reviewed journal.

8. (sasa2012threenoveltruncating pages 3-4): Ghadir Sasa, Albert Ribes-Zamora, Nya D. Nelson, and Alison A. Bertuch. Three novel truncating tinf2 mutations causing severe dyskeratosis congenita in early childhood. Clinical Genetics, 81:470-478, May 2012. URL: https://doi.org/10.1111/j.1399-0004.2011.01658.x, doi:10.1111/j.1399-0004.2011.01658.x. This article has 118 citations and is from a peer-reviewed journal.

9. (tomcikova2018whyisit pages 1-2): D. Tomcikova, A. Gerinec, B. Busanyova, M. Gresikova, S. Biskup, and K. Hortnagel. Why is it necessary to examine retina when the patient suffers from aplastic anemia? Bratislavske lekarske listy, 119 5:275-277, Jan 2018. URL: https://doi.org/10.4149/bll_2018_051, doi:10.4149/bll_2018_051. This article has 7 citations.

10. (karremann2020reveszsyndromerevisited pages 4-7): Michael Karremann, Eva Neumaier-Probst, Frank Schlichtenbrede, Fabian Beier, Tim H. Brümmendorf, Friedrich W. Cremer, Peter Bader, and Matthias Dürken. Revesz syndrome revisited. Orphanet Journal of Rare Diseases, Oct 2020. URL: https://doi.org/10.1186/s13023-020-01553-y, doi:10.1186/s13023-020-01553-y. This article has 39 citations and is from a peer-reviewed journal.

11. (karremann2020reveszsyndromerevisited pages 9-11): Michael Karremann, Eva Neumaier-Probst, Frank Schlichtenbrede, Fabian Beier, Tim H. Brümmendorf, Friedrich W. Cremer, Peter Bader, and Matthias Dürken. Revesz syndrome revisited. Orphanet Journal of Rare Diseases, Oct 2020. URL: https://doi.org/10.1186/s13023-020-01553-y, doi:10.1186/s13023-020-01553-y. This article has 39 citations and is from a peer-reviewed journal.

12. (nelson2018thecterminalextension pages 1-3): Nya D. Nelson, Lois M. Dodson, Laura Escudero, Ann T. Sukumar, Christopher L. Williams, Ivana Mihalek, Alessandro Baldan, Duncan M. Baird, and Alison A. Bertuch. The c-terminal extension unique to the long isoform of the shelterin component tin2 enhances its interaction with trf2 in a phosphorylation- and dyskeratosis congenita cluster-dependent fashion. Jun 2018. URL: https://doi.org/10.1128/mcb.00025-18, doi:10.1128/mcb.00025-18. This article has 34 citations and is from a domain leading peer-reviewed journal.

13. (sasa2012threenoveltruncating pages 1-3): Ghadir Sasa, Albert Ribes-Zamora, Nya D. Nelson, and Alison A. Bertuch. Three novel truncating tinf2 mutations causing severe dyskeratosis congenita in early childhood. Clinical Genetics, 81:470-478, May 2012. URL: https://doi.org/10.1111/j.1399-0004.2011.01658.x, doi:10.1111/j.1399-0004.2011.01658.x. This article has 118 citations and is from a peer-reviewed journal.

14. (roake2021tissuespecifictelomereshortening pages 1-2): Caitlin M. Roake, Marisa Juntilla, Rajni Agarwal-Hashmi, Steven Artandi, and Christin S. Kuo. Tissue-specific telomere shortening and degenerative changes in a patient with tinf2 mutation and dyskeratosis congenita. Human Pathology: Case Reports, 25:200517, Sep 2021. URL: https://doi.org/10.1016/j.ehpc.2021.200517, doi:10.1016/j.ehpc.2021.200517. This article has 6 citations.

15. (rolles2024inheritedtelomerebiology pages 12-14): Benjamin Rolles, Mareike Tometten, Robert Meyer, Martin Kirschner, Fabian Beier, and Tim H. Brümmendorf. Inherited telomere biology disorders: pathophysiology, clinical presentation, diagnostics, and treatment. Transfusion Medicine and Hemotherapy, 51:292-309, Jul 2024. URL: https://doi.org/10.1159/000540109, doi:10.1159/000540109. This article has 23 citations and is from a peer-reviewed journal.

16. (rolles2024inheritedtelomerebiology pages 10-12): Benjamin Rolles, Mareike Tometten, Robert Meyer, Martin Kirschner, Fabian Beier, and Tim H. Brümmendorf. Inherited telomere biology disorders: pathophysiology, clinical presentation, diagnostics, and treatment. Transfusion Medicine and Hemotherapy, 51:292-309, Jul 2024. URL: https://doi.org/10.1159/000540109, doi:10.1159/000540109. This article has 23 citations and is from a peer-reviewed journal.

17. (NCT06817590 chunk 1): Suneet Agarwal. Nucleoside Therapy in Patients With Telomere Biology Disorders. Suneet Agarwal. 2025. ClinicalTrials.gov Identifier: NCT06817590

18. (NCT01659606 chunk 1): Suneet Agarwal. Radiation- and Alkylator-free Bone Marrow Transplantation Regimen for Patients With Dyskeratosis Congenita. Boston Children's Hospital. 2012. ClinicalTrials.gov Identifier: NCT01659606

19. (rolles2024inheritedtelomerebiology pages 14-15): Benjamin Rolles, Mareike Tometten, Robert Meyer, Martin Kirschner, Fabian Beier, and Tim H. Brümmendorf. Inherited telomere biology disorders: pathophysiology, clinical presentation, diagnostics, and treatment. Transfusion Medicine and Hemotherapy, 51:292-309, Jul 2024. URL: https://doi.org/10.1159/000540109, doi:10.1159/000540109. This article has 23 citations and is from a peer-reviewed journal.

20. (savage2022dyskeratosiscongenitaand pages 5-6): Sharon A. Savage. Dyskeratosis congenita and telomere biology disorders. Hematology. American Society of Hematology. Education Program, 2022 1:637-648, Dec 2022. URL: https://doi.org/10.1182/hematology.2022000394, doi:10.1182/hematology.2022000394. This article has 119 citations.

21. (NCT04959188 chunk 1): Needs Assessment for Individuals and Families Affected by Dyskeratosis Congenita (DC) and Related Telomere Biology Disorders (TBD). National Cancer Institute (NCI). 2021. ClinicalTrials.gov Identifier: NCT04959188

22. (carvalho2022recentadvancesin pages 7-9): Vinicius S Carvalho, Willian R Gomes, and Rodrigo T Calado. Recent advances in understanding telomere diseases. Faculty Reviews, Oct 2022. URL: https://doi.org/10.12703/r/11-31, doi:10.12703/r/11-31. This article has 24 citations.

23. (NCT01659606 chunk 2): Suneet Agarwal. Radiation- and Alkylator-free Bone Marrow Transplantation Regimen for Patients With Dyskeratosis Congenita. Boston Children's Hospital. 2012. ClinicalTrials.gov Identifier: NCT01659606

24. (NCT06817590 chunk 2): Suneet Agarwal. Nucleoside Therapy in Patients With Telomere Biology Disorders. Suneet Agarwal. 2025. ClinicalTrials.gov Identifier: NCT06817590

25. (batista2011telomereshorteningand pages 1-3): Luis F. Z. Batista, Matthew F. Pech, Franklin L. Zhong, Ha Nam Nguyen, Kathleen T. Xie, Arthur J. Zaug, Sharon M. Crary, Jinkuk Choi, Vittorio Sebastiano, Athena Cherry, Neelam Giri, Marius Wernig, Blanche P. Alter, Thomas R. Cech, Sharon A. Savage, Renee A. Reijo Pera, and Steven E. Artandi. Telomere shortening and loss of self-renewal in dyskeratosis congenita ips cells. Nature, 474:399-402, May 2011. URL: https://doi.org/10.1038/nature10084, doi:10.1038/nature10084. This article has 316 citations and is from a highest quality peer-reviewed journal.

26. (nelson2018thecterminalextension pages 30-33): Nya D. Nelson, Lois M. Dodson, Laura Escudero, Ann T. Sukumar, Christopher L. Williams, Ivana Mihalek, Alessandro Baldan, Duncan M. Baird, and Alison A. Bertuch. The c-terminal extension unique to the long isoform of the shelterin component tin2 enhances its interaction with trf2 in a phosphorylation- and dyskeratosis congenita cluster-dependent fashion. Jun 2018. URL: https://doi.org/10.1128/mcb.00025-18, doi:10.1128/mcb.00025-18. This article has 34 citations and is from a domain leading peer-reviewed journal.

27. (nelson2018thecterminalextension pages 8-10): Nya D. Nelson, Lois M. Dodson, Laura Escudero, Ann T. Sukumar, Christopher L. Williams, Ivana Mihalek, Alessandro Baldan, Duncan M. Baird, and Alison A. Bertuch. The c-terminal extension unique to the long isoform of the shelterin component tin2 enhances its interaction with trf2 in a phosphorylation- and dyskeratosis congenita cluster-dependent fashion. Jun 2018. URL: https://doi.org/10.1128/mcb.00025-18, doi:10.1128/mcb.00025-18. This article has 34 citations and is from a domain leading peer-reviewed journal.

Artifacts

• Edison artifact artifact-00

Reference Validation

Checked with linkml-reference-validator 0.2.1.

All extracted references resolved successfully.

Term Validation

Checked with linkml-term-validator 0.4.5, through the ols: adapter.

Terms the report names something else

These identifiers resolve, so nothing about them looks wrong, and the ontology calls them something unrelated to what the report calls them. That usually means the identifier is not the one the sentence needs:

• MONDO:0009990 (5 mentions) - the report calls it "if available"; MONDO calls it Revesz syndrome

Obsolete terms

These terms are real but deprecated. Citing one is not a fabrication; it does mean the report is naming something the ontology has retired:

• GO:0000784 (GO_0000784) (2 mentions) - replaced by GO:0000781